Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.43 |
| ▸ | GUSB | P08236 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30988951 | 0.94 | LMNA (0.50) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL16516489 | 0.81 | ALDH1A1 (0.46) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL29256804 | 0.81 | GLA (0.53) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL9887938 | 0.80 | LMNA (0.76) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL6866191 | 0.76 | LMNA (0.61) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL12004733 | 0.76 | MEN1 (0.47) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL3466860 | 0.76 | LMNA (0.60) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL3466171 | 0.75 | LMNA (0.59) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL3467394 | 0.75 | LMNA (0.59) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL30990360 | 0.75 | ALDH1A1 (0.52) | LMNAALDH1A1MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344384-A | Compounds and uses thereof | 丹诺医药(苏州）有限公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-2015025283-A2 | DUAL ACTION CARBONIC ANHYDRASE INHIBITORS | STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO-CLINIC" (NL) | 2015-02-26 | — | — | WO | disclosed |
| WO-2015025283-A2 | DUAL ACTION CARBONIC ANHYDRASE INHIBITORS | STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO-CLINIC" (NL) | 2015-02-26 | — | — | WO | disclosed |
| US-7678791-B2 | Nitroheteroaryl-containing rifamycin derivatives | CUMBRE IP VENTURES, L.P. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008008480-A2 | NITROHETEROARYL-CONTAINING RIFAMYCIN DERIVATIVES | CUMBRE PHARMACEUTICALS INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | NRDC, FNTB, RIF1 | LMNA 2973/4885ALDH1A1 1997/4885MAPK1 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.